Drug intelligence / Profile preview

l-carnitine l-tartrate + maltodextrin

Development stage: Unknown
Lead developer: Lonza
Administration: Oral

Overview

L-carnitine L-tartrate + maltodextrin is a combination used primarily in research studies. L-carnitine L-tartrate consists of 68% elemental L-carnitine and 32% tartaric acid, while maltodextrin typically serves as a placebo or carrier. L-carnitine plays a critical role in energy production by transporting long-chain fatty acids into the mitochondria for oxidation. This combination has been studied for potential benefits in exercise performance, reduction of oxidative stress, and management of metabolic parameters.

Targets

SLC25A20 (Carnitine/acylcarnitine translocase)SLC7A1 (Cationic amino acid transporter 1)CPT2 (Carnitine O-palmitoyltransferase 2)

Beyond the preview

Go deeper on l-carnitine l-tartrate + maltodextrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-carnitine l-tartrate + maltodextrin.

Explore the full profile